Top

Published in:

01-12-2017 | Original Research

Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation

Authors: Mark Korpics, Alec M. Block, Basel Altoos, Brendan Martin, Kyle Carey, James Welsh, Matthew M. Harkenrider, Abhishek A. Solanki

Published in: Journal of Radiation Oncology | Issue 4/2017

Abstract

Objectives

Most historic trials demonstrating the outcomes with bladder-preserving radiotherapy (RT) used 64–66 Gy. However, newer data suggest improved outcomes with dose escalation up to 70 Gy. Our objective was to explore the impact of dose escalation on overall survival (OS) and to identify the optimal radiotherapy (RT) dose in patients with muscle-invasive bladder cancer (MIBC) treated with curative bladder-preserving RT.

Methods

We conducted a retrospective cohort study of patients with cT2–4 N0–3 M0 transitional cell MIBC who were treated with curative RT (60–70 Gy in 1.8–2.0 Gy/fraction) using the National Cancer Database. Univariable (UVA) and multivariable (MVA) frailty survival analyses were employed to identify the association of dose escalation to 67–70 Gy, as well as different RT dose subgroups within 60–66 Gy, and OS.

Results

In total, 2531 patients met eligibility criteria. The 2-year OS was 53 and 56%, respectively, for patients receiving 60–66 and 67–70 Gy (p = .25). On MVA, there was no significant difference in survival for patients receiving 67–70 vs. 60–66 Gy (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.76–1.10; p = .33). Compared to doses of 64–66 Gy, OS was worse with 60–61 Gy (HR, 1.33; 95% CI, 1.17–1.52; p < .0001) but there was no difference in OS with 62–63 Gy (HR, 1.11; 95% CI, 0.96–1.28; p = .15) after adjusting for clinical T stage and Charlson-Deyo comorbidity score.

Conclusions

When treating patients with MIBC with curative bladder-preserving radiotherapy, RT doses of 62–66 Gy have improved OS compared to lower doses, while dose escalation to 67–70 Gy does not improve survival. Our study does not support deviating from the standard of 64–66 Gy.

Siegel R, Miller K, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. doi:10.3322/caac.21254 CrossRefPubMed

Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374(9685):239–249. doi:10.1016/S0140-6736(09)60491-8 CrossRefPubMed

Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866. doi:10.1056/Nejmoa022148 CrossRefPubMed

Zehnder P, Studer UE, Skinner EC et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186(4):1261–1268. doi:10.1016/j.juro.2011.06.004 CrossRefPubMed

Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32(34):3801–3809. doi:10.1200/JCO.2014.57.5548 CrossRefPubMedPubMedCentral

Arcangeli G, Arcangeli S, Strigari L (2015) A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 94(1):105–115. doi:10.1016/j.critrevonc.2014.11.007 CrossRefPubMed

Solanki AA, Martin B, Korpics M, Small C, Harkenrider MM, Mitin T (2016) Variability of radiation oncologists’ chemoradiotherapy patterns of care and the impact of multidisciplinary clinics in muscle-invasive bladder cancer. In: American Society for Radiation Oncology 58th Annual Meeting. Boston

Ploussard G, Daneshmand S, Efstathiou JA et al (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 66(1):120–137. doi:10.1016/j.eururo.2014.02.038 CrossRefPubMed

Pos FJ, Hart G, Schneider C, Sminia P (2006) Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 64(4):1168–1173. doi:10.1016/j.ijrobp.2005.09.023 CrossRefPubMed

10.

Murthy V, Masodkar R, Kalyani N et al (2016) Clinical outcomes with dose-escalated adaptive radiation therapy for urinary bladder cancer: a prospective study. Int J Radiat Oncol Biol Phys 94(1):60–66. doi:10.1016/j.ijrobp.2015.09.010 CrossRefPubMed

11.

Hafeez S, Warren-Oseni K, McNair HA et al (2016) Prospective study delivering simultaneous integrated high dose tumour boost (up to 70Gy) with image guided adaptive radiotherapy (IGART) for the radical treatment of localized muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys 94(2016):1022–1030. doi:10.1016/j.ijrobp.2015.12.379 CrossRefPubMed

12.

Gray PJ, Fedewa SA, Shipley WU et al (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 63(5):823–829. doi:10.1016/j.eururo.2012.11.015 CrossRefPubMed

13.

Newman LA, Lee CT, Parekh LP et al (2006) Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer 106(1):188–195. doi:10.1002/cncr.21592 CrossRefPubMed

14.

National Comprehensive Cancer Network. Bladder cancer (version 2.2017). https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed March 10, 2017

15.

Lin DY, Wei LJ, Ying Z (1993) Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 80(3):557–572CrossRef

16.

James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477–1488. doi:10.1056/NEJMoa1106106 CrossRefPubMed

17.

Rodel C, Grabenbauer GG, Kühn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20(14):3061–3071. doi:10.1200/JCO.2002.11.027 CrossRefPubMed

18.

Chung PWM, Bristow RG, Milosevic MF et al (2007) Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25(4):303–309. doi:10.1016/j.urolonc.2006.09.015 CrossRefPubMed

19.

Perdonà S, Autorino R, Damiano R et al (2008) Bladder-sparing, combined- modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 112(1):75–83. doi:10.1002/cncr.23137 CrossRefPubMed

20.

Plataniotis GA, Dale RG (2013) Radio-chemotherapy for bladder cancer: contribution of chemotherapy on local control. World J Radiol 5(8):267–274. doi:10.4329/wjr.v5.i8.267 CrossRefPubMedPubMedCentral

21.

Syndikus I, Morgan R, Sydes M, Graham J, Dearnaley D (2010) Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 77(3):773–783. doi:10.1016/j.ijrobp.2009.05.052 CrossRefPubMedPubMedCentral

22.

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose–volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76(3):S123–S129. doi:10.1016/j.ijrobp.2009.03.078 CrossRefPubMedPubMedCentral

23.

Majewski W, MacIejewski B, Majewski S, Suwinski R, Miszczyk L, Tarnawski R (2004) Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 60(1):60–70. doi:10.1016/j.ijrobp.2004.02.056 CrossRefPubMed

24.

Søndergaard J, Høyer M, Petersen JB, Wright P, Grau C, Muren LP (2009) The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol 48(2):238–244. doi:10.1080/02841860802251575 CrossRefPubMed

25.

Søndergaard J, Holmberg M, Jakobsen AR, Agerbæk M, Muren LP, Høyer M (2014) A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol 53(10):1321–1328. doi:10.3109/0284186X.2014.928418 CrossRefPubMed

26.

Burridge N, Amer A, Marchant T et al (2006) Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction. Int J Radiat Oncol Biol Phys 66(3):892–897. doi:10.1016/j.ijrobp.2006.07.013 CrossRefPubMed

Title: Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation
Authors: Mark Korpics
Alec M. Block
Basel Altoos
Brendan Martin
Kyle Carey
James Welsh
Matthew M. Harkenrider
Abhishek A. Solanki
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2017
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-017-0319-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Defining an “ideal” continuous dose-volume constraint curve using literature recommended individual dose-volume thresholds for reducing rectal toxicity from external beam prostate radiation therapy

Fractionation trends in breast cancer and implications in partial breast irradiation

Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience

Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review

Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC)

Influence of radiation treatment technique on outcome and toxicity in anal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer